Short Interest in Nyxoah SA (NASDAQ:NYXH) Expands By 29.0%

Nyxoah SA (NASDAQ:NYXH) was the target of a significant growth in short interest in January. As of January 30th, there was short interest totaling 288,814 shares, a growth of 29.0% from the January 15th total of 223,806 shares. Based on an average trading volume of 61,235 shares, the short-interest ratio is presently 4.7 days. Currently, 0.8% of the shares of the company are short sold. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 61,235 shares, the short-interest ratio is presently 4.7 days.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on NYXH shares. Piper Sandler restated an “overweight” rating and set a $9.00 target price (down previously from $12.00) on shares of Nyxoah in a research report on Friday, November 14th. Stifel Nicolaus reduced their price target on Nyxoah from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Nyxoah Price Performance

Shares of NYXH traded up $0.05 during midday trading on Monday, hitting $4.43. The company’s stock had a trading volume of 20,729 shares, compared to its average volume of 46,861. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.40. Nyxoah has a one year low of $4.10 and a one year high of $11.87. The stock has a market capitalization of $150.89 million, a price-to-earnings ratio of -1.78 and a beta of 1.55. The company’s fifty day simple moving average is $4.79 and its two-hundred day simple moving average is $5.32.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.13). Nyxoah had a negative net margin of 1,457.97% and a negative return on equity of 101.99%. The business had revenue of $2.31 million during the quarter, compared to analyst estimates of $1.95 million. As a group, equities analysts expect that Nyxoah will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

Institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. increased its stake in shares of Nyxoah by 35.6% in the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after buying an additional 3,353 shares during the period. Bank of America Corp DE boosted its position in Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after acquiring an additional 3,303 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Nyxoah in the 3rd quarter worth about $98,000. Deutsche Bank AG lifted its stake in shares of Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the period. Finally, Shay Capital LLC bought a new stake in shares of Nyxoah during the 2nd quarter valued at about $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.